Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 65 of the 230 sources its claims cite were checked for support.
Abstract
Background: Bone and soft-tissue sarcomas are rare, heterogeneous malignancies whose surveillance remains dominated by imaging despite substantial molecular diversity and variable patterns of relapse. Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) offer minimally invasive approaches for monitoring tumor biology, but their performance in sarcoma depends strongly on subtype, disease burden, assay design, and biological shedding. Methods: This narrative review synthesizes evidence published from 2015 to 2026 on ctDNA and CTCs for baseline risk assessment, treatment-response monitoring, minimal residual disease (MRD) detection, molecular relapse, and integration with imaging-based surveillance in bone and soft-tissue sarcomas. Results: Current evidence supports a genomics-guided framework in which liquid-biopsy strategy is selected according to sarcoma subtype, molecular architecture, and clinical purpose. ctDNA is the most mature analyte, with best-supported evidence in osteosarcoma, where tumor-informed assays predict postoperative relapse, and in translocation-associated sarcomas, where breakpoint-guided assays enable highly specific longitudinal monitoring. Copy-number-based approaches are relevant for complex-karyotype tumors, while mutation-, methylation-, fragmentomic-, and RNA-based strategies may be useful in selected contexts. However, detection rates vary, false-negative results occur in low-shedding or low-volume disease, and clinical utility for changing treatment remains incompletely established. CTCs provide complementary cellular and prognostic information, particularly in osteosarcoma, but remain limited by platform heterogeneity and incomplete standardization. Conclusion: Liquid biopsy may refine risk stratification, support treatment-response assessment, clarify indeterminate imaging findings, and identify molecular relapse in selected sarcoma patients. At present, it should be interpreted as an adjunct to imaging and specialist multidisciplinary care rather than as a replacement for standard radiologic surveillance.
Overview
CoChat Summary
TL;DR
This narrative review argues that liquid biopsy in bone and soft-tissue sarcomas should be “genomics-guided,” meaning the assay should match the tumor’s molecular architecture and the clinical question rather than using one universal platform. ctDNA has the strongest near-term support, especially for baseline risk, treatment response, MRD, and molecular relapse in osteosarcoma and translocation-associated sarcomas, while CTCs are promising but less standardized.
Key findings
- The literature search identified 1284 records; after removing 347 duplicates, 937 titles/abstracts were screened, 124 full texts were assessed, and 53 sources were included in the narrative synthesis.
- In a Children’s Oncology Group cohort, ctDNA was detectable in more than half of newly diagnosed Ewing sarcoma and osteosarcoma cases, and detectable ctDNA was associated with inferior outcomes, particularly in localized Ewing sarcoma.
- In the largest osteosarcoma MRD cohort described, tumor-informed MRD panels were generated in 71 of 83 patients; postoperative ctDNA predicted inferior event-free survival and preceded positive imaging in 5 patients, with a mean lead time of 92.6 days.
- For osteosarcoma CTCs, one study detected CTCs in 30 of 32 patients before treatment (mean 14.06 ± 9.08), another in 28 of 30 patients (median 6 CTCs per 5 mL), and a third found CTCs in 43 of 50 patients with IMP3-positive CTC count showing AUC 0.873, 87.5% sensitivity, and 82.4% specificity for identifying metastasis.
Methods
- Narrative review of circulating biomarkers in bone and soft-tissue sarcomas, focusing on ctDNA, cfDNA, cfRNA, CTCs, and other circulating biomarkers for risk assessment, response monitoring, MRD, relapse surveillance, and imaging integration.
- Structured searches were conducted in PubMed and Scopus for studies published between January 2015 and 1 April 2026, with additional targeted searches and manual reference screening.
- Evidence was synthesized qualitatively; the paper states that it was not a formal systematic review or meta-analysis, and no quantitative meta-analysis was performed.
Limitations
- The paper states that most available studies are small, single-center, heterogeneous, and often retrospective, with variable sampling schedules and limited multicenter validation.
- It notes substantial assay heterogeneity across studies, including differences in plasma processing, cfDNA input, sequencing depth, error suppression, positivity thresholds, and handling of clonal hematopoiesis.
- It also emphasizes that low-shedding disease limits detection, so “ctDNA not detected” may reflect biology or technical sensitivity rather than true absence of disease; this is especially important in postoperative MRD and molecular relapse settings.
- Evident from the text: because this is a narrative review, its conclusions are based on selective synthesis rather than a fully systematic, quantitatively pooled evidence base.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
23 Valid · 4 Not valid · 59 Not checked · 60 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In early-stage solid tumors, ctDNA detection after curative-intent therapy has shown strong clinical validity for predicting future relapse”
What the sources say
- Supportedcites [9] Moding, 2021, Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease, Cancer Discov. source
The ‘Clinical sensitivity and specificity of current approaches’ section reviews studies testing ctDNA after curative-intent therapy for non-metastatic solid tumors and reports strong prognostic value for recurrence. It notes that a positive result has a high likelihood of relapse, while sensitivity is more limited. (LLM, conf=0.94)
- Supportedcites [10] Peng, Y., Mei, W., Ma, K., and Zeng, C. (2021). Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. Front. Oncol., 11. source
The Colorectal Cancer section reports that postoperative ctDNA positivity in stage I–III patients was associated with a seven-fold higher recurrence risk and that positivity after adjuvant chemotherapy was associated with a seventeen-fold higher risk. The Recurrence Risk Assessment section also links ctDNA detected after cystectomy to subsequent recurrence, supporting the claim across early-stage solid tumors. (LLM, conf=0.91)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In complex-karyotype sarcomas such as osteosarcoma, undifferentiated pleomorphic sarcoma, leiomyosarcoma, and dedifferentiated liposarcoma, individualized tumor-informed approaches or genome-wide copy-number strategies may be more appropriate [ 16 , 17 ].”
What the sources say
- Partly supportedcites [16] Fu, Y., Xu, Y., Liu, W., Zhang, J., Wang, F., Jian, Q., Huang, G., Zou, C., Xie, X., and Kim, A.H. (2024). Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma. EclinicalMedicine, 73. sourceExperimental — accuracy not yet measured
The Results and Discussion support an individualized tumor-informed approach for osteosarcoma because of its mutational heterogeneity. They do not extend that recommendation to undifferentiated pleomorphic sarcoma, leiomyosarcoma, or dedifferentiated liposarcoma. The Discussion says genome-wide copy-number detection has been explored in osteosarcoma, but describes its low sensitivity as making it unsuitable for longitudinal MRD detection. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [17] Audinot, 2024, ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: A translational study from the OS2006 trial, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. sourceExperimental — accuracy not yet measured
The Introduction (lines 114–120) supports genome-wide copy-number analysis for ctDNA detection in osteosarcoma. The Discussion (lines 337–350) mentions patient-specific panels used in other osteosarcoma studies, but does not establish that either approach is more appropriate across the other three named sarcomas. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“while methylation-based approaches may provide value in osteosarcoma, chordoma, and other low-mutation contexts [ 18 , 19 , 20 , 21 ].”
What the sources say
- Could not verifycites [18] Davies, 2021, Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations, Mol. Oncol. sourceExperimental — accuracy not yet measured
The Discussion addresses mutation-based ctDNA testing in chondrosarcoma and calls for additional biomarkers in tumours without IDH1/2 or GNAS mutations. Our copy does not address whether methylation-based approaches may help in osteosarcoma, chordoma, or other low-mutation contexts (searched: methylation, chordoma, osteosarcoma). (LLM, conf=0.75)
- Not checked yetcites [19] Zuccato, 2022, DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma, Neuro-Oncology source
- Could not verifycites [20] Gutteridge, 2017, Digital PCR analysis of circulating tumor DNA: A biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection, Cancer Med. sourceExperimental — accuracy not yet measured
The Results and Discussion describe mutation-targeted digital PCR in chondrosarcoma and other bone and soft-tissue tumors. Searches for methylation-based approaches, osteosarcoma, chordoma, and low-mutation contexts found no passage assessing the claimed potential value of methylation-based methods. (LLM, conf=0.75)
- Not checked yetcites [21] Kara, 2022, Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA, Eur. J. Cancer
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
None of the sources cited for this claim have been checked yet.
In the paper
“In the postoperative and post-treatment setting, radiologic interpretation may be further complicated by fibrosis, necrosis, inflammation, postsurgical change, and stable residual abnormalities that do not reliably distinguish treatment effect from viable disease [ 6 , 7 , 8 ].”
What the sources say
- Not checked yetcites [6] Vilanova, 2025, Soft tissue tumor imaging in adults: European Society of Musculoskeletal Radiology–Guidelines 2024: Imaging immediately after neoadjuvant therapy in soft tissue sarcoma, soft tissue tumor surveillance, and the role of interventional radiology, Eur. Radiol.
- Not checked yetcites [7] Stanborough, 2022, ACR Appropriateness Criteria® malignant or aggressive primary musculoskeletal tumor—Staging and surveillance: 2022 update, J. Am. Coll. Radiol. source
- Could not verifycites [8] Dammerer, 2020, Follow-up strategies for primary extremity soft-tissue sarcoma in adults: A systematic review of the published literature, In Vivo sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“although its clinical utility for directing treatment escalation or de-escalation remains under prospective evaluation [ 9 , 10 ].”
What the sources say
- Supportedcites [9] Moding, 2021, Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease, Cancer Discov. source
The paper’s “Future directions > Prospective clinical trials” section says that the clinical utility of ctDNA MRD for personalizing therapy in solid tumors remains to be determined and that interventional trials are underway. It specifically describes trials testing escalation and de-escalation of adjuvant or consolidation therapy. The “Adjuvant therapy to improve outcomes” section also notes limited evidence that either strategy improves patient outcomes. (LLM, conf=0.94)
- Supportedcites [10] Peng, Y., Mei, W., Ma, K., and Zeng, C. (2021). Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. Front. Oncol., 11. source
The Challenges and Future Directions section (page not available) says ctDNA-guided adjuvant treatment may be avoided for some patients in the future, calls for additional prospective studies, and cautions against withholding treatment solely on a negative test. The Conclusion (page not available) discusses adjusting adjuvant-treatment intensity according to ctDNA findings while saying that more studies are needed to validate its clinical effectiveness. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
77 more claims · 16 with their cited sources checked
Create a free account to see all 146 claims and to verify the 165 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 51
Citations
Cites
Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513 · cited 2×
“Current guidelines continue to rely on radiologic assessment, particularly chest imaging for metastatic surveillance and MRI or site-specific imaging for local disease control [1,2,6–8].”
UK guidelines for the management of soft tissue sarcomas
Dangoor, A., Seddon, B., Gerrand, C., Grimer, R., Whelan, J., & Judson, I. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0060-4 · Cited by 477
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325 · cited 8×
“It requires substantially greater analytical sensitivity than baseline genotyping because tumor-derived DNA may be present at very low levels after surgery or definitive therapy [5,9–12].”
InfluentialPeng, Y., Mei, W., Ma, K., & Zeng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763790 · Cited by 167
Shulman, D. S., Klega, K., Imamovic-Tuco, A., Clapp, A., Nag, A., Thorner, A. R., Van Allen, E., Ha, G., Lessnick, S. L., Gorlick, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0212-9 · Cited by 149 · cited 3×
“Shulman et al. [31] ctDNA was detectable in 53% of newly diagnosed Ewing sarcoma and 57% of osteosarcoma cases.”
InfluentialHarmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance
Greytak, S. R., Engel, K. B., Parpart-Li, S., Murtaza, M., Bronkhorst, A. J., Pertile, M. D., & Moore, H. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3015 · Cited by 140 · cited 4×
“Published work differs in plasma-processing protocols, cfDNA input, sequencing depth, error suppression, assay type, positivity thresholds, timing of blood collection, and correlation with imaging or clinical endpoints [11,12,40].”
InfluentialGodsey, J. H., Silvestro, A., Barrett, J. C., Bramlett, K., Chudova, D., Deras, I., Dickey, J., Hicks, J., Johann, D. J., Leary, R., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa164 · Cited by 104 · cited 7×
“Future studies should report pre-analytical and analytical variables transparently, including plasma volume, tube type, processing delay, cfDNA input, limit of detection, limit of quantification, tumor fraction when available, and handling of clonal hematopoiesis [5,11,12,40].”
InfluentialRecommendations for Cell-Free DNA Assay Validations
Lockwood, C. M., Borsu, L., Cankovic, M., Earle, J. S. L., Gocke, C. D., Hameed, M., Jordan, D., Lopategui, J. R., Pullambhatla, M., Reuther, J., et al. (2023) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.09.004 · Cited by 96 · cited 9×
“Future studies should report pre-analytical and analytical variables transparently, including plasma volume, tube type, processing delay, cfDNA input, limit of detection, limit of quantification, tumor fraction when available, and handling of clonal hematopoiesis [5,11,12,40].”
InfluentialDetection of circulating tumor DNA in patients with osteosarcoma
Barris, D. M., Weiner, S. B., Dubin, R. A., Fremed, M., Zhang, X., Piperdi, S., Zhang, W., Maqbool, S., Gill, J., Roth, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24268 · Cited by 63 · cited 1×
“…ctDNA, bone sarcoma cfDNA, cfRNA fusion-gene analysis, chordoma monitoring, non-metastatic soft-tissue sarcoma profiling, structural-variant detection, and personalized sarcoma ctDNA monitoring cohorts, remain exploratory and require prospective validation before clinical implementation [41–47].”
Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention
Tazzari, M., Bergamaschi, L., Vita, A. D., Collini, P., Barisella, M., Bertolotti, A., Ibrahim, T., Pasquali, S., Castelli, C., & Vallacchi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147518 · Cited by 56
DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma
Zuccato, J. A., Patil, V., Mansouri, S., Liu, J. C., Nassiri, F., Mamatjan, Y., Chakravarthy, A., Karimi, S., Almeida, J. P., Bernat, A.-L., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noab235 · Cited by 53
Shukla, N. N., Patel, J. A., Magnan, H., Zehir, A., You, D., Tang, J., Meng, F., Samoila, A., Slotkin, E. K., Ambati, S. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00028 · Cited by 52
Gitto, S., Cuocolo, R., Huisman, M., Messina, C., Albano, D., Omoumi, P., Kotter, E., Maas, M. M., van Ooijen, P. M. A., & Sconfienza, L. M. (2024) · Insights into Imaging · doi:10.1186/s13244-024-01614-x · Cited by 49
Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas
Braig, D., Becherer, C., Bickert, C., Braig, M., Claus, R., Eisenhardt, A. E., Heinz, J., Scholber, J., Herget, G. W., Bronsert, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32216 · Cited by 42
Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H.-Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0987 · Cited by 42
Gutteridge, A., Rathbone, V. M., Gibbons, R., Bi, M., Archard, N., Davies, K. E. J., Brown, J., Plagnol, V., Pillay, N., Amary, F., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1146 · Cited by 38
Vanni, S., Fausti, V., Fonzi, E., Liverani, C., Miserocchi, G., Spadazzi, C., Cocchi, C., Calabrese, C., Gurrieri, L., Riva, N., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086926 · Cited by 38
Audinot, B., Drubay, D., Gaspar, N., Mohr, A., Cordero, C., Marec-Bérard, P., Lervat, C., Piperno-Neumann, S., Jimenez, M., Mansuy, L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.006 · Cited by 38
Fu, Y., Xu, Y., Liu, W., Zhang, J., Wang, F., Jian, Q., Huang, G., Zou, C., Xie, X., Kim, A. H., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102697 · Cited by 37 · cited 10×
“During treatment, the most consistent observation is that falling ctDNA levels tend to parallel response, whereas persistent or rising ctDNA suggests resistant or progressive disease [13,16,22,30].”
InfluentialVita, A. D., Vanni, S., Fausti, V., Cocchi, C., Recine, F., Miserocchi, G., Liverani, C., Spadazzi, C., Bassi, M., Gessaroli, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111564 · Cited by 34
Wu, Z.-J., Tan, J.-C., Qin, X., Liu, B., & Yuan, Z.-C. (2018) · Cancer Management and Research · doi:10.2147/cmar.s176515 · Cited by 33 · cited 2×
“In one study, CTCs were detected in 30 of 32 osteosarcoma patients before treatment, with a mean pretreatment CTC count of 14.06 ± 9.08 and no CTCs detected in 10 healthy volunteers [27].”
InfluentialLiquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?
van der Laan, P., van Houdt, W. J., van den Broek, D., Steeghs, N., & van der Graaf, W. T. A. (2021) · Biomedicines · doi:10.3390/biomedicines9101315 · Cited by 31
Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma
Li, M., Lu, Y., Long, Z., Li, M., Kong, J., Chen, G., & Wang, Z. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100236 · Cited by 27
Seidel, M. G., Kashofer, K., Moser, T., Thueringer, A., Liegl-Atzwanger, B., Leithner, A., Szkandera, J., Benesch, M., El-Heliebi, A., & Heitzer, E. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.926405 · Cited by 24
Mu, H., Zuo, D., Chen, J., Liu, Z., Wang, Z., Yang, L., Shi, Q., & Hua, Y. (2022) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2022.0279 · Cited by 23
Mc Connell, L., Gazdova, J., Beck, K., Srivastava, S., Harewood, L., Stewart, J., Hübschmann, D., Stenzinger, A., Glimm, H., Heilig, C. E., et al. (2020) · Cancers · doi:10.3390/cancers12123627 · Cited by 22
Mattox, A. K., Yang, B., Douville, C., Lo, S.-F., Sciubba, D., Wolinsky, J. P., Gokaslan, Z. L., Robison, J., Blair, C., Jiao, Y., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa173 · Cited by 21
Association of circulating tumor cells and IMP3 expression with metastasis of osteosarcoma
Dai, S., Shao, X., Wei, Q., Du, S., Hou, C., Li, H., & Jin, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.819357 · Cited by 20
Demoret, B., Gregg, J., Liebner, D. A., Tinoco, G., Lenobel, S., & Chen, J. L. (2019) · Cancers · doi:10.3390/cancers11121829 · Cited by 18 · cited 3×
“First, most studies are limited by small cohort sizes, single-center designs, heterogeneous histologic inclusion, and variable sampling schedules [4,16,22,32–36].”
Genotyping of Circulating Free DNA Enables Monitoring of Tumor Dynamics in Synovial Sarcomas
Eisenhardt, A. E., Brugger, Z., Lausch, U., Kiefer, J., Zeller, J., Runkel, A., Schmid, A., Bronsert, P., Wehrle, J., Leithner, A., et al. (2022) · Cancers · doi:10.3390/cancers14092078 · Cited by 18
The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients
Eastley, N., Sommer, A., Ottolini, B., Neumann, R., Luo, J.-L., Hastings, R. K., McCulloch, T., Esler, C. P., Shaw, J. A., Ashford, R. U., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124483 · Cited by 17
Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas
Tsoi, K. M., Gokgoz, N., Darville-O'Quinn, P., Prochazka, P., Malekoltojari, A., Griffin, A. M., Ferguson, P. C., Wunder, J. S., & Andrulis, I. L. (2021) · Bone & Joint Research · doi:10.1302/2046-3758.109.bjr-2021-0014.r1 · Cited by 17 · cited 3×
“First, most studies are limited by small cohort sizes, single-center designs, heterogeneous histologic inclusion, and variable sampling schedules [4,16,22,32–36].”
Stanborough, R., Demertzis, J. L., Wessell, D. E., Lenchik, L., Ahlawat, S., Baker, J. C., Banks, J., Caracciolo, J. T., Garner, H. W., Hentz, C., et al. (2022) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2022.09.015 · Cited by 17
Lyskjær, I., Davies, C., Strobl, A., Hindley, J., James, S., Lalam, R. K., Cross, W., Hide, G., Rankin, K. S., Jeys, L., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13102 · Cited by 16 · cited 5×
“In chondrosarcoma, IDH1/2-or GNAS-mutant ctDNA detection has been proposed for diagnosis, risk stratification, and residual disease assessment in molecularly informative tumors [18,20].”
InfluentialSmolle, M. A., Seidel, M. G., Kashofer, K., Liegl-Atzwanger, B., Sadoghi, P., Müller, D. A., & Leithner, A. (2025) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-024-05711-w · Cited by 16
DAMMERER, D., VAN BEECK, A., SCHNEEWEISS, V., & SCHWABEGGER, A. (2020) · In Vivo · doi:10.21873/invivo.12140 · Cited by 14
Circulating Plasma Tumor DNA Is Superior to Plasma Tumor RNA Detection in Ewing Sarcoma Patients
Bodlak, A., Chang, K., Channel, J., Treece, A. L., Donaldson, N., Cost, C. R., Garrington, T. P., Greffe, B., Luna-Fineman, S., Sopfe, J., et al. (2021) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.04.003 · Cited by 12 · cited 2×
“Similarly, plasma tumor DNA appears more reproducible than plasma tumor RNA in Ewing sarcoma, suggesting that cfRNA should remain investigational rather than being presented as equivalent to ctDNA for routine monitoring [37].”
Blanchi, J., Taleb, S., Bayle, A., Verret, B., Toulmonde, M., Spalato‐ceruso, M., Dubos, P., Laizet, Y., Alame, M., Khalifa, E., et al. (2023) · Cancer Communications · doi:10.1002/cac2.12461 · Cited by 12
Unlocking the Potential of ctDNA in Sarcomas: A Review of Recent Advances
Aiyer, S., Kim, T.-H., Collier, K., Pollock, R., Verschraegen, C., Stover, D. G., & Tinoco, G. (2025) · Cancers · doi:10.3390/cancers17061040 · Cited by 11 · cited 1×
“The contemporary literature reinforces that ctDNA technologies are clinically promising but remain early in sarcoma, with ongoing barriers related to assay selection, disease burden, low tumor fraction, pre-analytical variability, and clinical validation [49].”
Eisenhardt, A. E., Schmid, A., Esser, J., Brugger, Z., Lausch, U., Kiefer, J., Braig, M., Runkel, A., Wehrle, J., Claus, R., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01523-x · Cited by 10
Anderson, C. J., Yang, H., Parsons, J., Ahrens, W. A., Jagosky, M. H., Hsu, J. H., Patt, J. C., Kneisl, J. S., & Steuerwald, N. M. (2025) · Clinical Orthopaedics & Related Research · doi:10.1097/corr.0000000000003161 · Cited by 10
Novel Molecular Methods in Soft Tissue Sarcomas: From Diagnostics to Theragnostics
Frazzette, N., & Jour, G. (2025) · Cancers · doi:10.3390/cancers17071215 · Cited by 10
Investigating the Use of Circulating Tumor DNA for Sarcoma Management
Darville-O’Quinn, P., Gökgöz, N., Tsoi, K. M., Andrulis, I. L., & Wunder, J. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216539 · Cited by 8
Li, G., Feng, P., Lin, Y.-Y., & Liang, P. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1613133 · Cited by 8
Circulating tumor DNA – A potential aid in the management of chordomas
Frederico, S. C., Darling, C., Zhang, X., Huq, S., Agnihotri, S., Gardner, P. A., Snyderman, C. H., Wang, E. W., & Zenonos, G. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1016385 · Cited by 7
Furukawa, N., Hasegawa, N., Kubota, D., Nakamura, Y., Tanaka, H., Iwata, S., Kawai, A., Saito, T., Takagi, T., Kohsaka, S., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13950-2 · Cited by 5
Schmid, A., Lausch, U., Runkel, A., Kiefer, J., Pauli, T., Boerries, M., Bogner, B., Eisenhardt, S. U., & Braig, D. (2025) · Cancer Medicine · doi:10.1002/cam4.70704 · Cited by 4
Joch, S., Smolle, M. A., Kashofer, K., Thüringer, A., Szkandera, J., Benesch, M., El-Heliebi, A., Liegl-Atzwanger, B., Leithner, A., & Seidel, M. G. (2024) · Oncology Research and Treatment · doi:10.1159/000543223 · Cited by 2 · cited 10×
“During treatment, the most consistent observation is that falling ctDNA levels tend to parallel response, whereas persistent or rising ctDNA suggests resistant or progressive disease [13,16,22,30].”
InfluentialClinical insights into circulating free-DNA in patients with bone sarcomas and ewing sarcoma
Aran, V., Cavalcanti, A. D. S., Meohas, W., Delocco, B. C., Perini, J. A., Pino, J., Guimaräes, J. A. M., Moura‐Neto, V., & Duarte, M. E. L. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100661 · Cited by 2
Research works printed but not linked: 4
- Vilanova, 2025, Soft tissue tumor imaging in adults: European Society of Musculoskeletal Radiology–Guidelines 2024: Imaging immediately after neoadjuvant therapy in soft tissue sarcoma, soft tissue tumor surveillance, and the role of interventional radiology, Eur. Radiol., 35, 3324
- Kara, 2022, Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA, Eur. J. Cancer, 168, 1
- Young, 2024, CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma—A short report, Cancer Drug Resist., 7, 51
- Nawan, 2022, Detection and Quantification of Circulating Tumor Cells in Salvaged Blood in Surgical Osteosarcoma Patients: A Pilot Study from a Tertiary Medical Center, Biomed. Environ. Sci., 35, 366
Cited by
Still being checked.
Metadata
- Authors
- Alabid, I., Yousef, A. J., Patni, M. M., Aloti, R. A., Qassim, Z. A.-A. M., Alothman-Agha, A. A., Hamdy, H. A., Noury, F. M., & Abdelfattah, M. T.
- Affiliations
- Ras al-Khaimah Medical and Health Sciences University (AE)
- Consultant Orthopaedic and Joint Replacement Surgeon, Department of Spine and Orthopaedic Surgery, RAK Hospital, Ras Al Khaimah 11393, United Arab Emirates
- Corresponding author
- Alabid, Ibrahim
- Patni, Mohamedanas Mohamedfaruk
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2026-07-15
- Volume
- 15
- Issue
- 14
- Pages
- 1271
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC13407131
- OpenAlex
- W7168401412
- Cited by
- 0
- References
- 51
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- liquid biopsy, bone sarcoma, soft tissue sarcoma, osteosarcoma, circulating tumor DNA, circulating tumor cells, minimal residual disease, molecular relapse, treatment response monitoring, risk stratification
- MeSH terms
- Liquid Biopsy, Circulating Tumor DNA, Bone Neoplasms, Humans, Neoplastic Cells, Circulating, Sarcoma, Biomarkers, Tumor, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.